Core/Shell mRNA Vaccine Delivery via Lipid-Polymer Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mRNA-based cancer vaccines face challenges such as mRNA degradation by enzymes, interaction with non-antigen-presenting cells leading to adverse reactions, and inefficient internalization by antigen-presenting cells, limiting their effectiveness in stimulating robust anti-tumoral immunity.
Innovation Solution
A biocompatible core/shell composition is developed, where mRNA is encapsulated within a positively-charged polymer core protected by a hydrophilic lipid bilayer shell, enhancing stability and uptake by antigen-presenting cells like dendritic cells, and stimulating potent immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If mRNA is delivered naked or with simple condensation, then manufacturing is simple, but mRNA degradation by enzymes occurs and reliability is poor
Solution Approach 1:
The patent employs a composite delivery system consisting of a lipid bilayer shell encapsulating a polymer-mRNA complex core. The lipid shell provides enzymatic protection while the polyplex core enables efficient cellular delivery, creating a composite material that simultaneously achieves stability and reliability without complex manufacturing procedures.
2Productivity
If mRNA is packaged with protamine, then cellular uptake is enhanced, but mRNA degradation by plasma and tissue RNases increases due to exposed naked mRNA
Solution Approach 1:
The patent implements a nested structure where the mRNA-polymer complex (polyplex) is encapsulated within a lipid bilayer shell. This nested arrangement protects the mRNA from external RNases while maintaining the polyplex's cellular uptake efficiency, effectively resolving the contradiction between enhanced delivery and increased degradation vulnerability.
Solution Approach 2:
The lipid bilayer shell acts as a flexible protective barrier that encapsulates the polyplex core. This thin film structure provides enzymatic protection while allowing the underlying polyplex to maintain its cellular interaction capabilities, thus preserving productivity while reducing harmful degradation.
3Object-generated harmful factors
If mRNA interacts with all immune cells, then immune stimulation occurs, but adverse reactions are triggered due to non-specific interactions
Solution Approach 1:
The lipid bilayer shell serves as an intermediary between the mRNA payload and the biological environment. It enables controlled interaction with antigen-presenting cells while preventing non-specific interactions with other immune cells, thus maintaining beneficial immune stimulation while minimizing adverse reactions through selective mediation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The core/shell structure significantly enhances the potency of mRNA vaccines by protecting mRNA from degradation and improving internalization, leading to more effective antigen processing and presentation, thereby inducing robust anti-tumoral immunity.
Implementation Method 1
mRNA is encapsulated within a positively-charged polymer core
Implementation Method 2
protected by a hydrophilic lipid bilayer shell, enhancing stability
Implementation Method 3
improving internalization, leading to more effective antigen processing and presentation
Data Source
Figure 1A~1L
Figure 2
Figure 3A~3H
AI summary
Disclosed are biocompatible core/shell compositions suitable for the delivery of populations of mRNA molecules to mammalian cells. The disclosed core-shell structured multicomponent compositions are optimized for the delivery of mRNAs encoding one or more cancer- or tumor-specific antigens to a population of antigen presenting cells, including, for example, human dendritic cells, macrophages and B cells. Also disclosed are methods for use of these compositions as therapeutic cancer vaccines.